To amend the Federal Food, Drug, and Cosmetic Act with respect to postapproval study requirements for certain controlled substances, and for other purposes.
USA115th CongressHR-5811| House
| Updated: 6/20/2018
Jerry McNerney
Democratic Representative
California
Health, Education, Labor, and Pensions Committee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Long-Term Opioid Efficacy Act of 2018 This bill expands the authority of the Food and Drug Administration (FDA) to require post-approval studies or clinical trials with respect to controlled substances (e.g., opioids).
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Ordered to be Reported (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held.
Mr. Walden moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H5243-5244)
DEBATE - The House proceeded with forty minutes of debate on H.R. 5811.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5243)
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5243)
Motion to reconsider laid on the table Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health
Drug safety, medical device, and laboratory regulationDrug trafficking and controlled substancesLicensing and registrationsPrescription drugs
To amend the Federal Food, Drug, and Cosmetic Act with respect to postapproval study requirements for certain controlled substances, and for other purposes.
USA115th CongressHR-5811| House
| Updated: 6/20/2018
Long-Term Opioid Efficacy Act of 2018 This bill expands the authority of the Food and Drug Administration (FDA) to require post-approval studies or clinical trials with respect to controlled substances (e.g., opioids).
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Ordered to be Reported (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held.
Mr. Walden moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H5243-5244)
DEBATE - The House proceeded with forty minutes of debate on H.R. 5811.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5243)
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5243)
Motion to reconsider laid on the table Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Jerry McNerney
Democratic Representative
California
Health, Education, Labor, and Pensions Committee, Energy and Commerce Committee
Health
Related Bills
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Drug safety, medical device, and laboratory regulationDrug trafficking and controlled substancesLicensing and registrationsPrescription drugs